At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 400 enrolled
Drug / intervention
Nivolumabbiological
Likely dose
Nivolumab 240 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Safety Study of Participants With Non-Small Cell Lung Cancer Receiving Second-Line Nivolumab Monotherapy in Asia
In Brief
A Phase 3 clinical trial evaluating Nivolumab for Lung Cancer and Non-Small Cell Lung Cancer. Completed, enrolled 400 participants across 30 sites in 2 countries.
Detailed Summary
The purpose of this study is to investigate the safety of patients in Asia with Non-Small Cell Lung Cancer (NSCLC)who are treated with Nivolumab monotherapy as a second line or third line treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer, Non-Small Cell Lung Cancer
CountriesChina, Thailand
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedJun 2017
Enrollment StartDec 2017
Primary CompletionJun 2021
TodayJul 2026
First PostedJun 22, 2017
Enrollment StartDec 25, 2017
Primary CompletionJun 8, 2021
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 9.0 years ago
Interventions
Nivolumabbiological
Intravenous infusion administered over 30 minutes at 240 mg